HP567 / Hinova Pharma - LARVOL DELTA

Discovery of HP567, a highly potent, brain-penetrating, and H1047R-selective PI3Kα inhibitor for the treatment of tumors bearing H1047R mutation (AACR 2024) - "Alpelisib is an FDA approved PI3Kα inhibitor targeting both wild-type (WT) and mutant PI3Kα, yet its clinical benefit is limited by the toxicities including hyperglycemia and rash (which are considered on target effects of WT- PI3Kα inhibition). The pre-clinical data supports the clinical development of HP567 for the treatment of tumors bearing PI3Kα H1047R mutations. Structure of HP567 will not be disclosed."

Late-breaking abstract • Breast Cancer • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma • Tongue Carcinoma • PIK3CA